Analysts' Actions: Halozyme, Hewlett-Packard, Immunogen, Sprouts

NEW YORK (TheStreet) -- RATINGS CHANGES

Halozyme Therapeutics (HALO) was upgraded at UBS to buy from neutral, UBS said. Driven on pipeline potential and undervalued valuation, UBS said. Twelve-month price target is $16.

Hewlett-Packard (HPQ) was upgraded at Goldman Sachs to neutral from sell. Management has executed far more effectively than anticipated, Goldman Sachs said. Twelve-month price target is $32.

Immunogen (IMGN) was upgraded at UBS to neutral from sell. Bullish outlook on Kadcyla and royalty revenue providing lower-risk valuation support, UBS said. Twelve-month price target is $13.

Points International (PCOM) was downgraded to hold at TheStreet Ratings.

Phoenix Companies (PNX) was upgraded to hold at TheStreet Ratings.

Springleaf (LEAF) was downgraded at Sterne Agee to neutral. Twelve-month price target is $28. Estimates were also cut, because of weakness in two units, Sterne Agee said.

Sprouts (SFM) was upgraded at Credit Suisse to outperform from neutral. Twelve-month price target is $34. Pullback provides an opportunity, Credit Suisse said. Twelve-month price target is $34.

Triumph (TGI) was upgraded at Credit Suisse to outperform from neutral. Company offers growth at a reasonable price, Credit Suisse said. Twelve-month price target is $88.

Theravance (THRX) was downgraded at Robert Baird to hold from buy. Valuation call, following the recent split, Robert Baird said.

Editor's note: To see analysts' stock comments and changes to price targets and earnings estimates, go to "Street Notes" which is available only to Real Money subscribers. To find out how to become a subscriber, please click here.

Follow TheStreet on Twitter and become a fan on Facebook.

Kass: Turn, Turn, Turn
Why Amazon Loves Local, and Why It Absolutely Shouldn't

This article was written by a staff member of TheStreet.

More from Stocks

Pegasystems Founder Explains Why He Has One of the Hottest Tech Stocks Around

Pegasystems Founder Explains Why He Has One of the Hottest Tech Stocks Around

9 Stocks Goldman Sachs Thinks Will Blow Wall Street's Performance Away in 2019

9 Stocks Goldman Sachs Thinks Will Blow Wall Street's Performance Away in 2019

Jim Cramer on U.S.-China Trade: The Media Has it Wrong

Jim Cramer on U.S.-China Trade: The Media Has it Wrong

Is Tesla's Stock Set to Nearly Double to $500?

Is Tesla's Stock Set to Nearly Double to $500?

Tesla's $78,000 Model 3 Is a Bargain. Here's Why

Tesla's $78,000 Model 3 Is a Bargain. Here's Why